ICAM1 and systemic lupus erythematosus: We previously reported that TI licensing of ASCs from SLE and SSc patients resulted in an elevation of ICAM1/VCAM-1 expression to the levels similar to HD/ASCs (Kuca-Warnawin et al., 2019), while the present results show similar changes in the synthesis of immunomodulatory mediators (Figures 5, 6).